
Aaron N Winn, Mpp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8572727/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program. Research in Social and Administrative Pharmacy, 2022, 18, 2517-2523.	3.0	3
2	The cost, survival, and qualityâ€ofâ€life implications of <scp>guidelineâ€discordant</scp> imaging for prostate cancer. Cancer Reports, 2022, 5, e1468.	1.4	5
3	The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. Journal of General Internal Medicine, 2022, 37, 415-438.	2.6	13
4	Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. Journal of Pain and Symptom Management, 2022, 63, e397-e417.	1.2	5
5	Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. Journal of General Internal Medicine, 2022, 37, 439-448.	2.6	8
6	Racial Disparities in Patient Activation: The Role of Economic Diversity. Western Journal of Nursing Research, 2021, 43, 517-529.	1.4	3
7	Teleâ€ICUs for COVIDâ€I9: A Look at National Prevalence and Characteristics of Hospitals Providing Teleintensive Care. Journal of Rural Health, 2021, 37, 133-141.	2.9	10
8	The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors. Journal of Women's Health, 2021, 30, 131-136.	3.3	3
9	The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. Cancer, 2021, 127, 93-102.	4.1	5
10	Impact of Pre-visit Contextual Data Collection on Patient-Physician Communication and Patient Activation: a Randomized Trial. Journal of General Internal Medicine, 2021, 36, 3321-3329.	2.6	9
11	The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments. Journal of General Internal Medicine, 2021, 36, 1858-1866.	2.6	5
12	Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. JAMA Health Forum, 2021, 2, e210673.	2.2	0
13	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	3.7	6
14	Pharmacy deserts and patients with breast cancer receipt of influenza vaccines. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e25-e31.	1.5	6
15	Clinician burnout during the COVID-19 pandemic before vaccine administration. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e71-e77.	1.5	27
16	An adapted two-step floating catchment area method accounting for urban–rural differences in spatial access to pharmacies. Journal of Pharmaceutical Health Services Research, 2021, 12, 69-77.	0.6	6
17	Analysis of Clinician and Patient Factors and Completion of Telemedicine Appointments Using Video. JAMA Network Open, 2021, 4, e2132917.	5.9	29
18	Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 765-768.	6.3	5

AARON N WINN, MPP

#	Article	IF	CITATIONS
19	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. Journal of the National Cancer Institute, 2020, 112, 1055-1062.	6.3	9
20	Newâ€onset persistent opioid use following breast cancer treatment in older adult women. Cancer, 2020, 126, 814-822.	4.1	14
21	Response to Strassels and Durham. Journal of the National Cancer Institute, 2020, 112, 1280-1280.	6.3	Ο
22	Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer. JAMA Network Open, 2020, 3, e2016858.	5.9	14
23	The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multiâ€state models to understand the dynamics of adherence. Pharmacoepidemiology and Drug Safety, 2020, 29, 550-557.	1.9	2
24	The association between drug industry payments and NCCN guideline panel membership Journal of Clinical Oncology, 2020, 38, 2068-2068.	1.6	3
25	The Impact of Previsit Contextual Data Collection on Patient-Provider Communication and Patient Activation: Study Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e20309.	1.0	3
26	Trends in a State Pharmaceutical Assistance Program for Low-income Older Adults in Wisconsin. Innovations in Pharmacy, 2020, 11, 9.	0.6	1
27	Factors associated with adjuvant endocrine therapy adherence in non-metastatic breast cancer Journal of Clinical Oncology, 2020, 38, 533-533.	1.6	0
28	The impact of the use of opioids among older breast cancer survivors and adverse events Journal of Clinical Oncology, 2020, 38, 12098-12098.	1.6	0
29	Identifying Heterogeneous Treatment Effects of Drug Policy in Quasi-experimental Settings. Current Epidemiology Reports, 2019, 6, 373-379.	2.4	1
30	Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis. American Journal of Obstetrics and Gynecology, 2019, 221, 318.e1-318.e9.	1.3	30
31	Clinician Encouragement and Online Health Record Usage. Journal of General Internal Medicine, 2019, 34, 2345-2347.	2.6	4
32	Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 145-149.	1.6	4
33	Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. Oncologist, 2019, 24, 632-639.	3.7	33
34	Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects. Medical Care, 2019, 57, 85-93.	2.4	11
35	Association of Use of Online Symptom Checkers With Patients' Plans for Seeking Care. JAMA Network Open, 2019, 2, e1918561.	5.9	54
36	More evidence on the limited impact of state oral oncology parity laws. Cancer, 2019, 125, 335-336.	4.1	3

AARON N WINN, MPP

#	Article	IF	CITATIONS
37	Making Sure We Don't Forget the Basics When Using Machine Learning. Journal of the National Cancer Institute, 2019, 111, 529-530.	6.3	2
38	Concurrent opioid and benzodiazepine use after breast cancer diagnosis Journal of Clinical Oncology, 2019, 37, 28-28.	1.6	0
39	Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Internal Medicine, 2018, 178, 854.	5.1	44
40	Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care, 2018, 41, 1227-1234.	8.6	66
41	Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncology, 2018, 4, 580.	7.1	19
42	Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncology, 2018, 4, e173598.	7.1	31
43	Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Medical Decision Making, 2018, 38, 942-953.	2.4	12
44	Untangling the Black-White mortality gap in endometrial cancer: a cohort simulation. American Journal of Obstetrics and Gynecology, 2017, 216, 324-325.	1.3	22
45	The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care. Current Diabetes Reports, 2017, 17, 40.	4.2	6
46	Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiology and Drug Safety, 2017, 26, 676-684.	1.9	6
47	Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ. Journal of Cancer Epidemiology, 2017, 2017, 1-6.	1.1	3
48	Reply to E. Ritchie et al. Journal of Clinical Oncology, 2017, 35, 1745-1746.	1.6	0
49	Pharmaceutical industry payments and oncologist drug selection Journal of Clinical Oncology, 2017, 35, 6510-6510.	1.6	Ο
50	The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiology and Drug Safety, 2016, 25, 953-959.	1.9	39
51	Socioeconomic Inequalities in Statin Adherence Under Universal Coverage. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 704-713.	2.2	32
52	Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 4323-4328.	1.6	97
53	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. American Journal of Preventive Medicine, 2016, 50, 241-248.	3.0	48
54	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood, 2015, 125, 1866-1869.	1.4	32

AARON N WINN, MPP

#	Article	IF	CITATIONS
55	The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Journal of the National Cancer Institute, 2015, 107, .	6.3	29
56	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. Journal of Oncology Practice, 2015, 11, 313-318.	2.5	5
57	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value in Health, 2015, 18, 308-314.	0.3	32
58	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results–Medicare Database. Biology of Blood and Marrow Transplantation, 2015, 21, 1823-1829.	2.0	30
59	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE, 2015, 10, e0121715.	2.5	28
60	Is the high cost of CML care "worth it"?. Journal of Clinical Oncology, 2015, 33, e17801-e17801.	1.6	1
61	Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2014, 32, 306-311.	1.6	442
62	Health Utilities for Children and Adults With Type 1 Diabetes. Medical Care, 2011, 49, 924-931.	2.4	34
63	The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care, 2010, 33, 1269-1274.	8.6	98